Interaction of Impaired Coronary Flow Reserve and Cardiomyocyte Injury on Adverse Cardiovascular Outcomes in Patients Without Overt Coronary Artery Disease

Background— Minimally elevated serum cardiac troponin reflects myocardial injury and is associated with increased mortality, even absent coronary artery disease (CAD). We sought to investigate the relationship between low-level troponin elevation and impaired coronary flow reserve (CFR), an integrated measure of coronary vasomotor function, and to assess their contributions to adverse outcomes in patients without overt CAD. Methods and Results— Consecutive patients (n=761) undergoing evaluation for suspected CAD with troponin before stress myocardial perfusion positron emission tomography were followed up (median, 2.8 years) for major adverse cardiovascular events, including cardiovascular death, nonfatal myocardial infarction, or late revascularization. Patients with flow-limiting CAD, left ventricular ejection fraction <40%, or revascularization within 60 days of imaging were excluded. CFR was quantified from stress/rest myocardial blood flow with the use of positron emission tomography. Compared with patients with negative troponin, those with at least 1 positive troponin (n=97) had higher pretest clinical scores, more renal dysfunction, and lower left ventricular ejection fraction and CFR. In adjusted analysis, impaired CFR remained independently associated with positive troponin (odds ratio, 2.18; 95% confidence interval, 1.37–3.47; P=0.001), and both impaired CFR and positive troponin were independently associated with major adverse cardiovascular events (hazard ratio, 2.25; 95% confidence interval, 1.31–3.86; P=0.003; and hazard ratio, 2.42; 95% confidence interval, 1.34–4.40; P=0.004, respectively). Impaired CFR and positive troponin identified patients at highest risk of major adverse cardiovascular events (log-rank P<0.0001), with a significant interaction (P<0.007) seen between CFR and troponin. Conclusions— In patients without overt CAD, impaired CFR was independently associated with minimally elevated troponin and major adverse cardiovascular events. Impaired CFR, here reflecting microvascular dysfunction, modified the effect of a positive troponin on adverse outcomes.

[1]  R. Blankstein,et al.  Abstract 15687: Myocardial Coronary Flow Reserve Predicts Adverse Clinical Outcomes Independently of Luminal Angiographic Score , 2013 .

[2]  Akshay S. Desai,et al.  Circulating Biomarkers in Patients with Heart Failure and Preserved Ejection Fraction , 2013, Current Heart Failure Reports.

[3]  S. Hokimoto,et al.  Coronary microvascular dysfunction and diastolic load correlate with cardiac troponin T release measured by a highly sensitive assay in patients with nonischemic heart failure. , 2013, Journal of the American College of Cardiology.

[4]  W. Paulus,et al.  A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.

[5]  O. Rimoldi,et al.  Inflammation and microvascular dysfunction in cardiac syndrome X patients without conventional risk factors for coronary artery disease. , 2013, JACC. Cardiovascular imaging.

[6]  P. Ridker,et al.  Inflammation, coronary flow reserve, and microvascular dysfunction: moving beyond cardiac syndrome X. , 2013, JACC. Cardiovascular imaging.

[7]  S. Solomon,et al.  Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. , 2013, Journal of the American College of Cardiology.

[8]  Jeroen J. Bax,et al.  Third universal definition of myocardial infarction. , 2012, Global heart.

[9]  Jeroen J. Bax,et al.  Third universal definition of myocardial infarction. , 2012, European heart journal.

[10]  R. Blankstein,et al.  Association Between Coronary Vascular Dysfunction and Cardiac Mortality in Patients With and Without Diabetes Mellitus , 2012, Circulation.

[11]  R. Blankstein,et al.  Coronary vascular dysfunction and prognosis in patients with chronic kidney disease. , 2012, JACC. Cardiovascular imaging.

[12]  O. Rimoldi,et al.  The coronary circulation and blood flow in left ventricular hypertrophy. , 2012, Journal of molecular and cellular cardiology.

[13]  U. Förstermann,et al.  Nitric oxide synthases: regulation and function. , 2012, European heart journal.

[14]  M. Pencina,et al.  Improved Cardiac Risk Assessment With Noninvasive Measures of Coronary Flow Reserve , 2011, Circulation.

[15]  P. Lamendola,et al.  [Coronary microvascular dysfunction. An update]. , 2011, Recenti progressi in medicina.

[16]  B. Chow,et al.  Impaired myocardial flow reserve on rubidium-82 positron emission tomography imaging predicts adverse outcomes in patients assessed for myocardial ischemia. , 2011, Journal of the American College of Cardiology.

[17]  N. Cook,et al.  Sensitive Cardiac Troponin T Assay and the Risk of Incident Cardiovascular Disease in Women With and Without Diabetes Mellitus: The Women's Health Study , 2011, Circulation.

[18]  M. Javadi,et al.  Prediction of Short-Term Cardiovascular Events Using Quantification of Global Myocardial Flow Reserve in Patients Referred for Clinical 82Rb PET Perfusion Imaging , 2011, The Journal of Nuclear Medicine.

[19]  W. Paulus,et al.  Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. , 2011, European heart journal.

[20]  A. Khera,et al.  Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. , 2010, JAMA.

[21]  M. Zhan,et al.  Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. , 2010, JAMA.

[22]  Christopher M O'Connor,et al.  Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. , 2010, Journal of the American College of Cardiology.

[23]  M. Pfeffer,et al.  A sensitive cardiac troponin T assay in stable coronary artery disease. , 2009, The New England journal of medicine.

[24]  Tobias Reichlin,et al.  Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. , 2009, The New England journal of medicine.

[25]  K. Gould,et al.  Does coronary flow trump coronary anatomy? , 2009, JACC. Cardiovascular imaging.

[26]  Oliver Gaemperli,et al.  Long-term prognostic value of 13N-ammonia myocardial perfusion positron emission tomography added value of coronary flow reserve. , 2009, Journal of the American College of Cardiology.

[27]  Georges El Fakhri,et al.  Reproducibility and Accuracy of Quantitative Myocardial Blood Flow Assessment with 82Rb PET: Comparison with 13N-Ammonia PET , 2009, Journal of Nuclear Medicine.

[28]  L. Lind,et al.  Prevalence and pathophysiological mechanisms of elevated cardiac troponin I levels in a population-based sample of elderly subjects. , 2008, European heart journal.

[29]  P. Jarolim,et al.  Implementation of a highly sensitive cardiac troponin I assay: test volumes, positivity rates and interpretation of results. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[30]  G. Taffet,et al.  Coronary Microvascular Dysfunction , 2007 .

[31]  C. Lotan,et al.  Acute coronary syndrome vs nonspecific troponin elevation: clinical predictors and survival analysis. , 2007, Archives of internal medicine.

[32]  Keiichiro Yoshinaga,et al.  What is the prognostic value of myocardial perfusion imaging using rubidium-82 positron emission tomography? , 2006, Journal of the American College of Cardiology.

[33]  A. Khera,et al.  Prevalence and Determinants of Troponin T Elevation in the General Population , 2006, Circulation.

[34]  P. Venge,et al.  Troponin I as a Predictor of Coronary Heart Disease and Mortality in 70-Year-Old Men: A Community-Based Cohort Study , 2006, Circulation.

[35]  M. Whooley,et al.  Prognostic value of low-level cardiac troponin-I elevations in patients without definite acute coronary syndromes , 2004 .

[36]  M. Cerqueira,et al.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. , 2002, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[37]  M. Cerqueira,et al.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. , 2002, Circulation.

[38]  O. Rimoldi,et al.  Heterogeneity of resting and hyperemic myocardial blood flow in healthy humans. , 2001, Cardiovascular research.

[39]  S. Goldhaber,et al.  Elevation of troponin I levels in patients without evidence of myocardial injury. , 1997, JAMA.

[40]  A. Morise,et al.  Development and validation of a clinical score to estimate the probability of coronary artery disease in men and women presenting with suspected coronary disease. , 1997, The American journal of medicine.

[41]  I. Olivotto,et al.  Effect of aging on myocardial perfusion reserve. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[42]  P. Grambsch,et al.  Martingale-based residuals for survival models , 1990 .

[43]  A. Wear CIRCULATION , 1964, The Lancet.

[44]  J. Alpert,et al.  The third universal definition of myocardial infarction , 2013 .

[45]  Cardiac Troponin T Measured by a Highly Sensitive Assay Predicts Coronary Heart Disease, Heart Failure, and Mortality in the Atherosclerosis Risk in Communities Study , 2011 .

[46]  L. Husmann,et al.  Long-Term Prognostic Value of 13 N-Ammonia Myocardial Perfusion Positron Emission Tomography Added Value of Coronary Flow Reserve , 2022 .